Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), recently announced that RLL has received tentative approval from the FDA to manufacture and market Tolterodine Tartrate Tablets, 1 mg and 2 mg. Total annual market sales for Tolterodine Tartrate Tablets were $98 million.
Tolterodine Tartrate Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
“We are pleased to receive tentative approval for Tolterodine Tartrate Tablets, which represents a future addition to our generic portfolio of products. Product will be made available at the time of final approval by the U.S. FDA,” according to Jim Meehan, Vice President of Sales and Marketing for RPI.
Ranbaxy Pharmaceuticals Inc. (“RPI”) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (“RLL”), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.
Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary “platform technologies,” resulting in a number of products under development. The Company is serving its customers in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 45 countries and manufacturing operations in 7 countries.